bimekizumab vs ORKA-002

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-17A/F · full Psoriasis pipeline

bimekizumab · Bimzelx

Marketed by UCB

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT03370133 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo- and active-controlled phase 3 trial involving 567 participants. Both prespecified clinical skin endpoints at week 16—PASI90 and Investigator’s Global Assessment response—were significantly better with bimekizumab than with placebo and ustekinumab (all p<0.001).

Next expected readout: March 2027 · NCT06506916 (registry estimate)

Reported efficacy

Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16; Percentage of Participants With an Investigator's Global Assessment (IGA) Response (Clear or Almost Clear With at Least 2-Category Improvement Relative to Baseline) at Week 16: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS) 86.2% vs Adalimumab (RS) 47.2% (met)

Result source: NCT03412747

ORKA-002

Developed by Oruka Therapeutics

Phase 2 in Psoriasismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2027 · NCT07474792 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbimekizumabORKA-002
PASI 7576.9% vs 2.4%+74.5 vs placebo320 mg Q4W · wk 4 · n 321NCT03370133
10 other results
  • 75.9% vs 1.2% 320 mg Q4W · wk 4 · n 349 · Phase 3 · secondary NCT03410992
  • 74% vs 3% Dosage Regimen 1 · wk 4 · n 100 · Phase 3 · secondary NCT06011733
  • 75% vs 0% 320 mg Q4W · wk 4 · n 32 · Phase 3 · secondary NCT05020249
  • 76.5% vs 31.4% 320 mg Q4W + 320 mg Q4W/Q8W · wk 4 · n 319 · Phase 3 · secondary NCT03412747
  • 71% vs 47.3% 320 mg Q4W · wk 4 · n 373 · Phase 3 · secondary NCT03536884
  • 93% vs 4.8% 320 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 83.7% vs 4.8% 480 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 81.4% vs 4.8% 160 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 85% vs 4.8% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · secondary NCT02905006
  • 61.5% vs 4.8% 64 mg Q4W · wk 12 · n 39 · Phase 2 · secondary NCT02905006
—Not reported
PASI 9085% vs 4.8%+80.2 vs placebo320 mg Q4W · wk 16 · n 321NCT03370133
48 other results
  • 90.8% vs 1.2% 320 mg Q4W · wk 16 · n 349 · Phase 3 · primary NCT03410992
  • 94% vs 3% Dosage Regimen 1 · wk 16 · n 100 · Phase 3 · primary NCT06011733
  • 81.3% vs 0% 320 mg Q4W · wk 16 · n 32 · Phase 3 · primary NCT05020249
  • 86.2% vs 47.2% 320 mg Q4W + 320 mg Q4W/Q8W · wk 16 · n 319 · Phase 3 · primary NCT03412747
  • 85% vs 2.4% 320 mg Q4W · wk 12 · n 321 · Phase 3 · secondary NCT03370133
  • 85.5% vs 74.3% 320 mg Q4W · wk 16 · n 373 · Phase 3 · secondary NCT03536884
  • 79.1% vs 0% 320 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 72.1% vs 0% 480 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 67.4% vs 0% 160 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 75% vs 0% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · primary NCT02905006
  • 46.2% vs 0% 64 mg Q4W · wk 12 · n 39 · Phase 2 · primary NCT02905006
  • 100% vs 83.8% 320 mg Q4W · wk 16 · n 33 · Phase 2 · secondary NCT03010527
  • 100% vs 81.1% 320 mg Q4W · wk 12 · n 33 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 320 mg Q4W · wk 8 · n 33 · Phase 2 · secondary NCT03010527
  • 86% vs 0% 320 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 97% vs 45.9% 320 mg Q4W · wk 4 · n 33 · Phase 2 · secondary NCT03010527
  • 96.7% vs 83.8% 480 mg Q4W / 320 mg Q4W · wk 16 · n 30 · Phase 2 · secondary NCT03010527
  • 96.7% vs 81.1% 480 mg Q4W / 320 mg Q4W · wk 12 · n 30 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 480 mg Q4W / 320 mg Q4W · wk 8 · n 30 · Phase 2 · secondary NCT03010527
  • 69.8% vs 0% 480 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 480 mg Q4W / 320 mg Q4W · wk 4 · n 30 · Phase 2 · secondary NCT03010527
  • 92.7% vs 83.8% 160 mg Q4W · wk 16 · n 55 · Phase 2 · secondary NCT03010527
  • 96.4% vs 81.1% 160 mg Q4W · wk 12 · n 55 · Phase 2 · secondary NCT03010527
  • 96.4% vs 67.6% 160 mg Q4W · wk 8 · n 55 · Phase 2 · secondary NCT03010527
  • 58.1% vs 0% 160 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 160 mg Q4W · wk 4 · n 55 · Phase 2 · secondary NCT03010527
  • 100% vs 83.8% 320 mg Q4W · wk 16 · n 6 · Phase 2 · secondary NCT03010527
  • 100% vs 81.1% 320 mg Q4W · wk 12 · n 6 · Phase 2 · secondary NCT03010527
  • 83.3% vs 67.6% 320 mg Q4W · wk 8 · n 6 · Phase 2 · secondary NCT03010527
  • 66.7% vs 45.9% 320 mg Q4W · wk 4 · n 6 · Phase 2 · secondary NCT03010527
  • 62.5% vs 83.8% 480 mg Q4W / 320 mg Q4W · wk 16 · n 8 · Phase 2 · secondary NCT03010527
  • 62.5% vs 81.1% 480 mg Q4W / 320 mg Q4W · wk 12 · n 8 · Phase 2 · secondary NCT03010527
  • 50% vs 67.6% 480 mg Q4W / 320 mg Q4W · wk 8 · n 8 · Phase 2 · secondary NCT03010527
  • 50% vs 45.9% 480 mg Q4W / 320 mg Q4W · wk 4 · n 8 · Phase 2 · secondary NCT03010527
  • 64.3% vs 83.8% 160 mg Q4W / 320 mg Q4W · wk 16 · n 14 · Phase 2 · secondary NCT03010527
  • 64.3% vs 81.1% 160 mg Q4W / 320 mg Q4W · wk 12 · n 14 · Phase 2 · secondary NCT03010527
  • 57.1% vs 67.6% 160 mg Q4W / 320 mg Q4W · wk 8 · n 14 · Phase 2 · secondary NCT03010527
  • 67.5% vs 0% 160 mg w/ LD Q4W · wk 8 · n 40 · Phase 2 · secondary NCT02905006
  • 42.9% vs 45.9% 160 mg Q4W / 320 mg Q4W · wk 4 · n 14 · Phase 2 · secondary NCT03010527
  • 100% vs 83.8% 64 mg Q4W · wk 16 · n 15 · Phase 2 · secondary NCT03010527
  • 78.9% vs 83.8% 64 mg Q4W / 160 mg Q4W · wk 16 · n 19 · Phase 2 · secondary NCT03010527
  • 100% vs 81.1% 64 mg Q4W · wk 12 · n 15 · Phase 2 · secondary NCT03010527
  • 78.9% vs 81.1% 64 mg Q4W / 160 mg Q4W · wk 12 · n 19 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 64 mg Q4W · wk 8 · n 15 · Phase 2 · secondary NCT03010527
  • 73.7% vs 67.6% 64 mg Q4W / 160 mg Q4W · wk 8 · n 19 · Phase 2 · secondary NCT03010527
  • 41% vs 0% 64 mg Q4W · wk 8 · n 39 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 64 mg Q4W · wk 4 · n 15 · Phase 2 · secondary NCT03010527
  • 42.1% vs 45.9% 64 mg Q4W / 160 mg Q4W · wk 4 · n 19 · Phase 2 · secondary NCT03010527
—Not reported
PASI 10061.7% vs 48.9%vs Secukinumab320 mg Q4W · wk 16 · n 373NCT03536884
10 other results
  • 58.6% vs 0% 320 mg Q4W · wk 16 · n 321 · Phase 3 · secondary NCT03370133
  • 68.2% vs 1.2% 320 mg Q4W · wk 16 · n 349 · Phase 3 · secondary NCT03410992
  • 65% vs 0% Dosage Regimen 1 · wk 16 · n 100 · Phase 3 · secondary NCT06011733
  • 21.9% vs 0% 320 mg Q4W · wk 16 · n 32 · Phase 3 · secondary NCT05020249
  • 60.8% vs 23.9% 320 mg Q4W + 320 mg Q4W/Q8W · wk 16 · n 319 · Phase 3 · secondary NCT03412747
  • 55.8% vs 0% 320 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 48.8% vs 0% 480 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 27.9% vs 0% 160 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 60% vs 0% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · secondary NCT02905006
  • 28.2% vs 0% 64 mg Q4W · wk 12 · n 39 · Phase 2 · secondary NCT02905006
—Not reported
sPGA 0/184.1% vs 4.8%+79.3 vs placebo320 mg Q4W · wk 16 · n 321NCT03370133
1 other result
  • 81.9% vs 4.8% 320 mg Q4W · wk 12 · n 321 · Phase 3 · secondary NCT03370133
—Not reported
DLQI, change—Trial running · NCT06506916—Not reported

PASI 75

bimekizumab
76.9% vs 2.4%+74.5 vs placebo320 mg Q4W · wk 4 · n 321NCT03370133
10 other results
  • 75.9% vs 1.2% 320 mg Q4W · wk 4 · n 349 · Phase 3 · secondary NCT03410992
  • 74% vs 3% Dosage Regimen 1 · wk 4 · n 100 · Phase 3 · secondary NCT06011733
  • 75% vs 0% 320 mg Q4W · wk 4 · n 32 · Phase 3 · secondary NCT05020249
  • 76.5% vs 31.4% 320 mg Q4W + 320 mg Q4W/Q8W · wk 4 · n 319 · Phase 3 · secondary NCT03412747
  • 71% vs 47.3% 320 mg Q4W · wk 4 · n 373 · Phase 3 · secondary NCT03536884
  • 93% vs 4.8% 320 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 83.7% vs 4.8% 480 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 81.4% vs 4.8% 160 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 85% vs 4.8% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · secondary NCT02905006
  • 61.5% vs 4.8% 64 mg Q4W · wk 12 · n 39 · Phase 2 · secondary NCT02905006
ORKA-002
—Not reported

PASI 90

bimekizumab
85% vs 4.8%+80.2 vs placebo320 mg Q4W · wk 16 · n 321NCT03370133
48 other results
  • 90.8% vs 1.2% 320 mg Q4W · wk 16 · n 349 · Phase 3 · primary NCT03410992
  • 94% vs 3% Dosage Regimen 1 · wk 16 · n 100 · Phase 3 · primary NCT06011733
  • 81.3% vs 0% 320 mg Q4W · wk 16 · n 32 · Phase 3 · primary NCT05020249
  • 86.2% vs 47.2% 320 mg Q4W + 320 mg Q4W/Q8W · wk 16 · n 319 · Phase 3 · primary NCT03412747
  • 85% vs 2.4% 320 mg Q4W · wk 12 · n 321 · Phase 3 · secondary NCT03370133
  • 85.5% vs 74.3% 320 mg Q4W · wk 16 · n 373 · Phase 3 · secondary NCT03536884
  • 79.1% vs 0% 320 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 72.1% vs 0% 480 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 67.4% vs 0% 160 mg Q4W · wk 12 · n 43 · Phase 2 · primary NCT02905006
  • 75% vs 0% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · primary NCT02905006
  • 46.2% vs 0% 64 mg Q4W · wk 12 · n 39 · Phase 2 · primary NCT02905006
  • 100% vs 83.8% 320 mg Q4W · wk 16 · n 33 · Phase 2 · secondary NCT03010527
  • 100% vs 81.1% 320 mg Q4W · wk 12 · n 33 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 320 mg Q4W · wk 8 · n 33 · Phase 2 · secondary NCT03010527
  • 86% vs 0% 320 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 97% vs 45.9% 320 mg Q4W · wk 4 · n 33 · Phase 2 · secondary NCT03010527
  • 96.7% vs 83.8% 480 mg Q4W / 320 mg Q4W · wk 16 · n 30 · Phase 2 · secondary NCT03010527
  • 96.7% vs 81.1% 480 mg Q4W / 320 mg Q4W · wk 12 · n 30 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 480 mg Q4W / 320 mg Q4W · wk 8 · n 30 · Phase 2 · secondary NCT03010527
  • 69.8% vs 0% 480 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 480 mg Q4W / 320 mg Q4W · wk 4 · n 30 · Phase 2 · secondary NCT03010527
  • 92.7% vs 83.8% 160 mg Q4W · wk 16 · n 55 · Phase 2 · secondary NCT03010527
  • 96.4% vs 81.1% 160 mg Q4W · wk 12 · n 55 · Phase 2 · secondary NCT03010527
  • 96.4% vs 67.6% 160 mg Q4W · wk 8 · n 55 · Phase 2 · secondary NCT03010527
  • 58.1% vs 0% 160 mg Q4W · wk 8 · n 43 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 160 mg Q4W · wk 4 · n 55 · Phase 2 · secondary NCT03010527
  • 100% vs 83.8% 320 mg Q4W · wk 16 · n 6 · Phase 2 · secondary NCT03010527
  • 100% vs 81.1% 320 mg Q4W · wk 12 · n 6 · Phase 2 · secondary NCT03010527
  • 83.3% vs 67.6% 320 mg Q4W · wk 8 · n 6 · Phase 2 · secondary NCT03010527
  • 66.7% vs 45.9% 320 mg Q4W · wk 4 · n 6 · Phase 2 · secondary NCT03010527
  • 62.5% vs 83.8% 480 mg Q4W / 320 mg Q4W · wk 16 · n 8 · Phase 2 · secondary NCT03010527
  • 62.5% vs 81.1% 480 mg Q4W / 320 mg Q4W · wk 12 · n 8 · Phase 2 · secondary NCT03010527
  • 50% vs 67.6% 480 mg Q4W / 320 mg Q4W · wk 8 · n 8 · Phase 2 · secondary NCT03010527
  • 50% vs 45.9% 480 mg Q4W / 320 mg Q4W · wk 4 · n 8 · Phase 2 · secondary NCT03010527
  • 64.3% vs 83.8% 160 mg Q4W / 320 mg Q4W · wk 16 · n 14 · Phase 2 · secondary NCT03010527
  • 64.3% vs 81.1% 160 mg Q4W / 320 mg Q4W · wk 12 · n 14 · Phase 2 · secondary NCT03010527
  • 57.1% vs 67.6% 160 mg Q4W / 320 mg Q4W · wk 8 · n 14 · Phase 2 · secondary NCT03010527
  • 67.5% vs 0% 160 mg w/ LD Q4W · wk 8 · n 40 · Phase 2 · secondary NCT02905006
  • 42.9% vs 45.9% 160 mg Q4W / 320 mg Q4W · wk 4 · n 14 · Phase 2 · secondary NCT03010527
  • 100% vs 83.8% 64 mg Q4W · wk 16 · n 15 · Phase 2 · secondary NCT03010527
  • 78.9% vs 83.8% 64 mg Q4W / 160 mg Q4W · wk 16 · n 19 · Phase 2 · secondary NCT03010527
  • 100% vs 81.1% 64 mg Q4W · wk 12 · n 15 · Phase 2 · secondary NCT03010527
  • 78.9% vs 81.1% 64 mg Q4W / 160 mg Q4W · wk 12 · n 19 · Phase 2 · secondary NCT03010527
  • 100% vs 67.6% 64 mg Q4W · wk 8 · n 15 · Phase 2 · secondary NCT03010527
  • 73.7% vs 67.6% 64 mg Q4W / 160 mg Q4W · wk 8 · n 19 · Phase 2 · secondary NCT03010527
  • 41% vs 0% 64 mg Q4W · wk 8 · n 39 · Phase 2 · secondary NCT02905006
  • 100% vs 45.9% 64 mg Q4W · wk 4 · n 15 · Phase 2 · secondary NCT03010527
  • 42.1% vs 45.9% 64 mg Q4W / 160 mg Q4W · wk 4 · n 19 · Phase 2 · secondary NCT03010527
ORKA-002
—Not reported

PASI 100

bimekizumab
61.7% vs 48.9%vs Secukinumab320 mg Q4W · wk 16 · n 373NCT03536884
10 other results
  • 58.6% vs 0% 320 mg Q4W · wk 16 · n 321 · Phase 3 · secondary NCT03370133
  • 68.2% vs 1.2% 320 mg Q4W · wk 16 · n 349 · Phase 3 · secondary NCT03410992
  • 65% vs 0% Dosage Regimen 1 · wk 16 · n 100 · Phase 3 · secondary NCT06011733
  • 21.9% vs 0% 320 mg Q4W · wk 16 · n 32 · Phase 3 · secondary NCT05020249
  • 60.8% vs 23.9% 320 mg Q4W + 320 mg Q4W/Q8W · wk 16 · n 319 · Phase 3 · secondary NCT03412747
  • 55.8% vs 0% 320 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 48.8% vs 0% 480 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 27.9% vs 0% 160 mg Q4W · wk 12 · n 43 · Phase 2 · secondary NCT02905006
  • 60% vs 0% 160 mg w/ LD Q4W · wk 12 · n 40 · Phase 2 · secondary NCT02905006
  • 28.2% vs 0% 64 mg Q4W · wk 12 · n 39 · Phase 2 · secondary NCT02905006
ORKA-002
—Not reported

sPGA 0/1

bimekizumab
84.1% vs 4.8%+79.3 vs placebo320 mg Q4W · wk 16 · n 321NCT03370133
1 other result
  • 81.9% vs 4.8% 320 mg Q4W · wk 12 · n 321 · Phase 3 · secondary NCT03370133
ORKA-002
—Not reported

DLQI, change

bimekizumab
—Trial running · NCT06506916
ORKA-002
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ORKA-002: no structured comparison results are available for Psoriasis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. bimekizumab: 4 of 4 rows · ORKA-002: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbimekizumab
Dropout rate
—320 mg Q4Wa
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 46 more results
—320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
—320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
—320 mg Q4W/Q8W
NCT03412747 · Phase 3 · Psoriasis · phase 3
—320 mg Q4W
NCT03410992 · Phase 3
—320 mg Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q8W
NCT03410992 · Phase 3
—320 mg Q4W/Q8W
NCT03410992 · Phase 3
—Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
—Dosage Regimen 2
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
—Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
100%320 mg Q4W
NCT03598790 · Phase 3 · registry result, not featured evidence
10.4%320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
15.1%320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence · combination
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
0%320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
5%320/160 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
0%64/32 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
—
NCT03230292 · Phase 2 · registry result, not featured evidence
—320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—320 mg
NCT03025542 · Phase 2 · registry result, not featured evidence
—320 mg + PBO
NCT03025542 · Phase 2 · registry result, not featured evidence · combination
—320 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—480 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—160 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—160 mg w/ LD Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—64 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—320 mg Q4Wa
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 46 more results
—320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
—320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
—320 mg Q4W/Q8W
NCT03412747 · Phase 3 · Psoriasis · phase 3
—320 mg Q4W
NCT03410992 · Phase 3
—320 mg Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q4W
NCT03410992 · Phase 3
—320 mg Q4W/Q8W
NCT03410992 · Phase 3
—320 mg Q4W/Q8W
NCT03410992 · Phase 3
—Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
—Dosage Regimen 2
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
—Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
34.3%320 mg Q4W
NCT03598790 · Phase 3 · registry result, not featured evidence
4%320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
6.3%320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence · combination
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
—320/160 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
—64/32 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
—
NCT03230292 · Phase 2 · registry result, not featured evidence
—320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
—320 mg
NCT03025542 · Phase 2 · registry result, not featured evidence
—320 mg + PBO
NCT03025542 · Phase 2 · registry result, not featured evidence · combination
—320 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—480 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—160 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—160 mg w/ LD Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
—64 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
Serious AEs
6.1%320 mg Q4Wa
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 46 more results
1.6%320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
2.5%320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
0.6%320 mg Q4W/Q8W
NCT03412747 · Phase 3 · Psoriasis · phase 3
1.7%320 mg Q4W
NCT03410992 · Phase 3
0%320 mg Q4W
NCT03410992 · Phase 3
4.7%320 mg Q4W/Q4W
NCT03410992 · Phase 3
0%320 mg Q4W/Q4W
NCT03410992 · Phase 3
3%320 mg Q4W/Q8W
NCT03410992 · Phase 3
0%320 mg Q4W/Q8W
NCT03410992 · Phase 3
3.1%Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
4.2%Dosage Regimen 2
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
1%Dosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
7.2%320 mg Q4W
NCT03598790 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
10.2%320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
4.9%320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
9.8%320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
9.8%320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
4%320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence · combination
2.7%320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
—320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
4.2%320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
3.7%320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
8.9%320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
11.1%320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
1.5%320 mg Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
6.8%320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
0%320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
0%320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
0%320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
0%320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
0%320 mg
NCT03766685 · Phase 3 · registry result, not featured evidence
10%320/160 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
14.3%64/32 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
7%
NCT03230292 · Phase 2 · registry result, not featured evidence
7.7%320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
6.3%160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
6.7%64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
5.9%320 mg
NCT03025542 · Phase 2 · registry result, not featured evidence
6.3%320 mg + PBO
NCT03025542 · Phase 2 · registry result, not featured evidence · combination
0%320 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
2.3%480 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
0%160 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
0%160 mg w/ LD Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
0%64 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
320 mg Q4Wa
nasopharyngitis 21.8% (placebo 8.4%)
oral candidiasis 15.2% (placebo 0%)
upper respiratory tract infection 9.1% (placebo 2.4%)
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 43 more results
320 mg Q4W
nasopharyngitis 9.3% (placebo 8.4%)
oral candidiasis 8.7% (placebo 0%)
headache 3.4% (placebo 0%)
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
320 mg Q4W
nasopharyngitis 20.3%
oral candidiasis 9.5%
diarrhoea 5.1%
NCT03412747 · Phase 3 · Psoriasis · phase 3
320 mg Q4W/Q8W
nasopharyngitis 16.8%
oral candidiasis 11.8%
upper respiratory tract infection 7.5%
NCT03412747 · Phase 3 · Psoriasis · phase 3
320 mg Q4W
nasopharyngitis 6.6% (placebo 4.7%)
oral candidiasis 6% (placebo 0%)
upper respiratory tract infection 4% (placebo 8.1%)
NCT03410992 · Phase 3
320 mg Q4W
nasopharyngitis 4.3% (placebo 4.7%)
neutropenia 4.3% (placebo 0%)
oral candidiasis 4.3% (placebo 0%)
NCT03410992 · Phase 3
320 mg Q4W/Q4W
oral candidiasis 11.3% (placebo 0%)
upper respiratory tract infection 11.3% (placebo 8.1%)
nasopharyngitis 10.4% (placebo 4.7%)
NCT03410992 · Phase 3
320 mg Q4W/Q4W
body tinea 14.3% (placebo 0%)
neutropenia 14.3% (placebo 0%)
psoriasis 14.3% (placebo 4.7%)
NCT03410992 · Phase 3
320 mg Q4W/Q8W
nasopharyngitis 23% (placebo 4.7%)
oral candidiasis 9% (placebo 0%)
upper respiratory tract infection 8% (placebo 8.1%)
NCT03410992 · Phase 3
320 mg Q4W/Q8W
dental caries 25% (placebo 1.2%)
impetigo 25% (placebo 1.2%)
rib fracture 25% (placebo 0%)
NCT03410992 · Phase 3
Dosage Regimen 1
upper respiratory tract infection 18.5% (placebo 6.1%)
injection site pain 5.4% (placebo 3%)
hyperlipidaemia 3.8% (placebo 6.1%)
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
Dosage Regimen 2
hepatic function abnormal 7.3% (placebo 0%)
eczema 5.2% (placebo 0%)
latent tuberculosis 5.2% (placebo 0%)
NCT06011733 · Phase 3 · registry result, not featured evidence · combination
Dosage Regimen 1
upper respiratory tract infection 21% (placebo 6.1%)
hyperlipidaemia 5% (placebo 6.1%)
injection site pain 5% (placebo 3%)
NCT06011733 · Phase 3 · registry result, not featured evidence
320 mg Q4W
nasopharyngitis 19.3%
oral candidiasis 16.1%
upper respiratory tract infection 8.2%
NCT03598790 · Phase 3 · registry result, not featured evidence
320 mg Q8W
corona virus infection 14.3%
nasopharyngitis 12.5%
oral candidiasis 10.4%
NCT03598790 · Phase 3 · registry result, not featured evidence
320 mg Q8W
corona virus infection 15%
nasopharyngitis 6.2%
oral candidiasis 5.8%
NCT03598790 · Phase 3 · registry result, not featured evidence
320 mg Q4W/Q8W
corona virus infection 19.5%
oral candidiasis 14.6%
dermatitis contact 9.8%
NCT03598790 · Phase 3 · registry result, not featured evidence
320 mg Q8W
corona virus infection 5.9%
oral candidiasis 5.9%
dermatitis contact 3.9%
NCT03598790 · Phase 3 · registry result, not featured evidence
320 mg Q4W
nasopharyngitis 16.6%
oral candidiasis 13.4%
upper respiratory tract infection 6.2%
NCT03536884 · Phase 3 · registry result, not featured evidence · combination
320 mg Q4W
nasopharyngitis 12.6%
oral candidiasis 10.5%
upper respiratory tract infection 4.3%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q8W
oral candidiasis 16.7%
nasopharyngitis 15.3%
upper respiratory tract infection 9.8%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q4W
oral candidiasis 13.3%
nasopharyngitis 11.6%
urinary tract infection 6.5%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q8W
nasopharyngitis 9.9%
oral candidiasis 8.5%
corona virus infection 7.8%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q8W
corona virus infection 22.2%
arthropod bite 11.1%
basal cell carcinoma 11.1%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q8W
corona virus infection 10.6%
oral candidiasis 6.1%
nasopharyngitis 4.5%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q4W/Q8W
corona virus infection 16.9%
oral candidiasis 8.5%
basal cell carcinoma 3.4%
NCT03536884 · Phase 3 · registry result, not featured evidence
320 mg Q4W
corona virus infection 21.9% (placebo 6.7%)
eczema 6.3% (placebo 0%)
tinea pedis 6.3% (placebo 0%)
NCT05020249 · Phase 3 · registry result, not featured evidence
320 mg
injection site pain 0%
injection site reaction 0%
NCT03766685 · Phase 3 · registry result, not featured evidence
320 mg
injection site pain 5.3%
injection site reaction 0%
NCT03766685 · Phase 3 · registry result, not featured evidence
320 mg
injection site pain 0%
injection site reaction 0%
NCT03766685 · Phase 3 · registry result, not featured evidence
320 mg
injection site reaction 5.3%
injection site pain 0%
NCT03766685 · Phase 3 · registry result, not featured evidence
320/160 mg
nasopharyngitis 45%
urinary tract infection 25%
alanine aminotransferase increased 10%
NCT04718896 · Phase 2 · registry result, not featured evidence
64/32 mg
nasopharyngitis 33.3%
upper respiratory tract infection 23.8%
pharyngitis 14.3%
NCT04718896 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 18.6%
nasopharyngitis 16.3%
gamma-glutamyltransferase increased 11.6%
NCT03230292 · Phase 2 · registry result, not featured evidence
320 mg Q4W
oral candidiasis 16.5%
nasopharyngitis 12.1%
upper respiratory tract infection 9.9%
NCT03010527 · Phase 2 · registry result, not featured evidence
160 mg Q4W
nasopharyngitis 13.5%
oral candidiasis 11.7%
upper respiratory tract infection 9%
NCT03010527 · Phase 2 · registry result, not featured evidence
64 mg Q4W
hypertension 13.3%
nasopharyngitis 13.3%
psoriasis 13.3%
NCT03010527 · Phase 2 · registry result, not featured evidence
320 mg
nasopharyngitis 23.5%
alanine aminotransferase increased 17.6%
gamma-glutamyltransferase increased 17.6%
NCT03025542 · Phase 2 · registry result, not featured evidence
320 mg + PBO
upper respiratory tract infection 18.8%
hyperkalaemia 12.5%
urinary tract infection 12.5%
NCT03025542 · Phase 2 · registry result, not featured evidence · combination
320 mg Q4W
nasopharyngitis 14% (placebo 4.8%)
oral candidiasis 7% (placebo 0%)
neutropenia 4.7% (placebo 0%)
NCT02905006 · Phase 2 · registry result, not featured evidence
480 mg Q4W
nasopharyngitis 9.3% (placebo 4.8%)
arthralgia 7% (placebo 0%)
headache 2.3% (placebo 0%)
NCT02905006 · Phase 2 · registry result, not featured evidence
160 mg Q4W
gamma-glutamyltransferase increased 7% (placebo 2.4%)
nasopharyngitis 7% (placebo 4.8%)
tonsillitis 4.7% (placebo 0%)
NCT02905006 · Phase 2 · registry result, not featured evidence
160 mg w/ LD Q4W
nasopharyngitis 7.5% (placebo 4.8%)
upper respiratory tract infection 7.5% (placebo 2.4%)
gamma-glutamyltransferase increased 5% (placebo 2.4%)
NCT02905006 · Phase 2 · registry result, not featured evidence
64 mg Q4W
nasopharyngitis 12.8% (placebo 4.8%)
upper respiratory tract infection 12.8% (placebo 2.4%)
arthralgia 5.1% (placebo 0%)
NCT02905006 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 43 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

bimekizumab

PASI 90 85% (n=321) vs 4.8% (n=83) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 116 more results
85% (n=321) vs 2.4% (n=83) placebo @ 12wk320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
81.9% (n=321) vs 55.8% (n=163) Ustekinumab @ 52wk320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
86.2% (n=319) vs 47.2% (n=159) Adalimumab @ 16wk320 mg Q4W + 320 mg Q4W/Q8W
NCT03412747 · Phase 3 · combination · Psoriasis · phase 3
85.1% (n=161) vs 51.6% (n=159) Adalimumab @ 24wk320 mg Q4W/Q8W
NCT03412747 · Phase 3 · Psoriasis · phase 3
86.1% (n=158) vs 51.6% (n=159) Adalimumab @ 24wk320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
85.6% (n=319) vs 51.6% (n=159) Adalimumab @ 24wk320 mg Q4W + 320 mg Q4W/Q8W
NCT03412747 · Phase 3 · combination · Psoriasis · phase 3
90.8% (n=349) vs 1.2% (n=86) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
85.5% (n=373) vs 74.3% (n=370) Secukinumab @ 16wk320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
81.3% (n=32) vs 0% (n=15) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
97% (n=33) vs 45.9% (n=37) placebo @ 4wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
66.7% (n=6) vs 45.9% (n=37) placebo @ 4wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=33) vs 67.6% (n=37) placebo @ 8wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
83.3% (n=6) vs 67.6% (n=37) placebo @ 8wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=33) vs 81.1% (n=37) placebo @ 12wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=6) vs 81.1% (n=37) placebo @ 12wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=33) vs 83.8% (n=37) placebo @ 16wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=6) vs 83.8% (n=37) placebo @ 16wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
93.9% (n=33) vs 89.2% (n=37) placebo @ 20wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
83.3% (n=6) vs 89.2% (n=37) placebo @ 20wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
97% (n=33) vs 83.8% (n=37) placebo @ 24wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
83.3% (n=6) vs 83.8% (n=37) placebo @ 24wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
97% (n=33) vs 91.9% (n=37) placebo @ 28wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
83.3% (n=6) vs 91.9% (n=37) placebo @ 28wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
97% (n=33) vs 91.9% (n=37) placebo @ 32wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
83.3% (n=6) vs 91.9% (n=37) placebo @ 32wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
97% (n=33) vs 91.9% (n=37) placebo @ 36wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
66.7% (n=6) vs 91.9% (n=37) placebo @ 36wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
87.9% (n=33) vs 89.2% (n=37) placebo @ 40wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
83.3% (n=6) vs 89.2% (n=37) placebo @ 40wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
87.9% (n=33) vs 89.2% (n=37) placebo @ 44wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
83.3% (n=6) vs 89.2% (n=37) placebo @ 44wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
87.9% (n=33) vs 91.9% (n=37) placebo @ 48wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
66.7% (n=6) vs 91.9% (n=37) placebo @ 48wk320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
79.1% (n=43) vs 0% (n=42) placebo @ 12wk320 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
86% (n=43) vs 0% (n=42) placebo @ 8wk320 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
100% (n=30) vs 45.9% (n=37) placebo @ 4wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
50% (n=8) vs 45.9% (n=37) placebo @ 4wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=30) vs 67.6% (n=37) placebo @ 8wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
50% (n=8) vs 67.6% (n=37) placebo @ 8wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
96.7% (n=30) vs 81.1% (n=37) placebo @ 12wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
62.5% (n=8) vs 81.1% (n=37) placebo @ 12wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
96.7% (n=30) vs 83.8% (n=37) placebo @ 16wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
62.5% (n=8) vs 83.8% (n=37) placebo @ 16wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
96.7% (n=30) vs 89.2% (n=37) placebo @ 20wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
62.5% (n=8) vs 89.2% (n=37) placebo @ 20wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
96.7% (n=30) vs 83.8% (n=37) placebo @ 24wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
75% (n=8) vs 83.8% (n=37) placebo @ 24wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
96.7% (n=30) vs 91.9% (n=37) placebo @ 28wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
50% (n=8) vs 91.9% (n=37) placebo @ 28wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
93.3% (n=30) vs 91.9% (n=37) placebo @ 32wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
50% (n=8) vs 91.9% (n=37) placebo @ 32wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
93.3% (n=30) vs 91.9% (n=37) placebo @ 36wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
50% (n=8) vs 91.9% (n=37) placebo @ 36wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
86.7% (n=30) vs 89.2% (n=37) placebo @ 40wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
50% (n=8) vs 89.2% (n=37) placebo @ 40wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
86.7% (n=30) vs 89.2% (n=37) placebo @ 44wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
50% (n=8) vs 89.2% (n=37) placebo @ 44wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
86.7% (n=30) vs 91.9% (n=37) placebo @ 48wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
50% (n=8) vs 91.9% (n=37) placebo @ 48wk480 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
72.1% (n=43) vs 0% (n=42) placebo @ 12wk480 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
69.8% (n=43) vs 0% (n=42) placebo @ 8wk480 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
100% (n=55) vs 45.9% (n=37) placebo @ 4wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
42.9% (n=14) vs 45.9% (n=37) placebo @ 4wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
96.4% (n=55) vs 67.6% (n=37) placebo @ 8wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
57.1% (n=14) vs 67.6% (n=37) placebo @ 8wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
96.4% (n=55) vs 81.1% (n=37) placebo @ 12wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
64.3% (n=14) vs 81.1% (n=37) placebo @ 12wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
92.7% (n=55) vs 83.8% (n=37) placebo @ 16wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
64.3% (n=14) vs 83.8% (n=37) placebo @ 16wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
89.1% (n=55) vs 89.2% (n=37) placebo @ 20wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
78.6% (n=14) vs 89.2% (n=37) placebo @ 20wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
85.5% (n=55) vs 83.8% (n=37) placebo @ 24wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
71.4% (n=14) vs 83.8% (n=37) placebo @ 24wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
90.9% (n=55) vs 91.9% (n=37) placebo @ 28wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
71.4% (n=14) vs 91.9% (n=37) placebo @ 28wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
89.1% (n=55) vs 91.9% (n=37) placebo @ 32wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
71.4% (n=14) vs 91.9% (n=37) placebo @ 32wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
85.5% (n=55) vs 91.9% (n=37) placebo @ 36wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
71.4% (n=14) vs 91.9% (n=37) placebo @ 36wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
83.6% (n=55) vs 89.2% (n=37) placebo @ 40wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
71.4% (n=14) vs 89.2% (n=37) placebo @ 40wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
81.8% (n=55) vs 89.2% (n=37) placebo @ 44wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
71.4% (n=14) vs 89.2% (n=37) placebo @ 44wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
80% (n=55) vs 91.9% (n=37) placebo @ 48wk160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
71.4% (n=14) vs 91.9% (n=37) placebo @ 48wk160 mg Q4W / 320 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
67.4% (n=43) vs 0% (n=42) placebo @ 12wk160 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
75% (n=40) vs 0% (n=42) placebo @ 12wk160 mg w/ LD Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
58.1% (n=43) vs 0% (n=42) placebo @ 8wk160 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
67.5% (n=40) vs 0% (n=42) placebo @ 8wk160 mg w/ LD Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
100% (n=15) vs 45.9% (n=37) placebo @ 4wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
42.1% (n=19) vs 45.9% (n=37) placebo @ 4wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=15) vs 67.6% (n=37) placebo @ 8wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
73.7% (n=19) vs 67.6% (n=37) placebo @ 8wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=15) vs 81.1% (n=37) placebo @ 12wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
78.9% (n=19) vs 81.1% (n=37) placebo @ 12wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=15) vs 83.8% (n=37) placebo @ 16wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
78.9% (n=19) vs 83.8% (n=37) placebo @ 16wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=15) vs 89.2% (n=37) placebo @ 20wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
84.2% (n=19) vs 89.2% (n=37) placebo @ 20wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=15) vs 83.8% (n=37) placebo @ 24wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
78.9% (n=19) vs 83.8% (n=37) placebo @ 24wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
93.3% (n=15) vs 91.9% (n=37) placebo @ 28wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
84.2% (n=19) vs 91.9% (n=37) placebo @ 28wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=15) vs 91.9% (n=37) placebo @ 32wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
73.7% (n=19) vs 91.9% (n=37) placebo @ 32wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=15) vs 91.9% (n=37) placebo @ 36wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
73.7% (n=19) vs 91.9% (n=37) placebo @ 36wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=15) vs 89.2% (n=37) placebo @ 40wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
78.9% (n=19) vs 89.2% (n=37) placebo @ 40wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=15) vs 89.2% (n=37) placebo @ 44wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
78.9% (n=19) vs 89.2% (n=37) placebo @ 44wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
100% (n=15) vs 91.9% (n=37) placebo @ 48wk64 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
68.4% (n=19) vs 91.9% (n=37) placebo @ 48wk64 mg Q4W / 160 mg Q4W
NCT03010527 · Phase 2 · registry result, not featured evidence
46.2% (n=39) vs 0% (n=42) placebo @ 12wk64 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
41% (n=39) vs 0% (n=42) placebo @ 8wk64 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
94% (n=100) vs 3% (n=33) placebo @ 16wkDosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
sPGA 0/1 84.1% (n=321) vs 4.8% (n=83) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 2 more results
81.9% (n=321) vs 4.8% (n=83) placebo @ 12wk320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
78.2% (n=321) vs 60.7% (n=163) Ustekinumab @ 52wk320 mg Q4W
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
PASI 100 58.6% (n=321) vs 0% (n=83) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 15 more results
60.8% (n=319) vs 23.9% (n=159) Adalimumab @ 16wk320 mg Q4W + 320 mg Q4W/Q8W
NCT03412747 · Phase 3 · combination · Psoriasis · phase 3
65.8% (n=161) vs 29.6% (n=159) Adalimumab @ 24wk320 mg Q4W/Q8W
NCT03412747 · Phase 3 · Psoriasis · phase 3
67.7% (n=158) vs 29.6% (n=159) Adalimumab @ 24wk320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
66.8% (n=319) vs 29.6% (n=159) Adalimumab @ 24wk320 mg Q4W + 320 mg Q4W/Q8W
NCT03412747 · Phase 3 · combination · Psoriasis · phase 3
68.2% (n=349) vs 1.2% (n=86) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
61.7% (n=373) vs 48.9% (n=370) Secukinumab @ 16wk320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
66.5% (n=215) vs 46.2% (n=370) Secukinumab @ 48wk320 mg Q4W/Q8W
NCT03536884 · Phase 3 · registry result, not featured evidence
73.5% (n=147) vs 46.2% (n=370) Secukinumab @ 48wk320 mg Q4W/Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
21.9% (n=32) vs 0% (n=15) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
55.8% (n=43) vs 0% (n=42) placebo @ 12wk320 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
48.8% (n=43) vs 0% (n=42) placebo @ 12wk480 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
27.9% (n=43) vs 0% (n=42) placebo @ 12wk160 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
60% (n=40) vs 0% (n=42) placebo @ 12wk160 mg w/ LD Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
28.2% (n=39) vs 0% (n=42) placebo @ 12wk64 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
65% (n=100) vs 0% (n=33) placebo @ 16wkDosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
IGA 0 58.6% (n=321) vs 0% (n=83) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 2 more results
69.6% (n=349) vs 1.2% (n=86) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
21.9% (n=32) vs 0% (n=15) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
PASI 75 76.9% (n=321) vs 2.4% (n=83) placebo @ 4wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 10 more results
76.5% (n=319) vs 31.4% (n=159) Adalimumab @ 4wk320 mg Q4W + 320 mg Q4W/Q8W
NCT03412747 · Phase 3 · combination · Psoriasis · phase 3
75.9% (n=349) vs 1.2% (n=86) placebo @ 4wk320 mg Q4W
NCT03410992 · Phase 3
71% (n=373) vs 47.3% (n=370) Secukinumab @ 4wk320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
75% (n=32) vs 0% (n=15) placebo @ 4wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
93% (n=43) vs 4.8% (n=42) placebo @ 12wk320 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
83.7% (n=43) vs 4.8% (n=42) placebo @ 12wk480 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
81.4% (n=43) vs 4.8% (n=42) placebo @ 12wk160 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
85% (n=40) vs 4.8% (n=42) placebo @ 12wk160 mg w/ LD Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
61.5% (n=39) vs 4.8% (n=42) placebo @ 12wk64 mg Q4W
NCT02905006 · Phase 2 · registry result, not featured evidence
74% (n=100) vs 3% (n=33) placebo @ 4wkDosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
Pain 77.3% (n=229) vs 16.7% (n=54) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 3 more results
78.8% (n=255) vs 9% (n=67) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
62.5% (n=24) vs 0% (n=10) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
86.1% (n=72) vs 14.3% (n=14) placebo @ 16wkDosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
Itch 76.6% (n=244) vs 13.1% (n=61) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 3 more results
75.5% (n=278) vs 5.6% (n=72) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
57.7% (n=26) vs 0% (n=12) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
84.1% (n=88) vs 8% (n=25) placebo @ 16wkDosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
Scaling 78.5% (n=246) vs 12.7% (n=63) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 3 more results
78% (n=286) vs 5.7% (n=70) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
64.3% (n=28) vs 0% (n=13) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
91.6% (n=95) vs 20% (n=30) placebo @ 16wkDosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
Scalp IGA 84.2% (n=285) vs 15.3% (n=72) placebo @ 16wk320 mg Q4W
responder rate · % of participants
NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3
show 2 more results
92.3% (n=310) vs 6.8% (n=74) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
86.2% (n=29) vs 7.1% (n=14) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
IGA 0/1 85.3% (n=319) vs 57.2% (n=159) Adalimumab @ 16wk320 mg Q4W + 320 mg Q4W/Q8W
responder rate · % of participants
NCT03412747 · Phase 3 · combination · Psoriasis · phase 3
show 7 more results
87% (n=161) vs 57.9% (n=159) Adalimumab @ 24wk320 mg Q4W/Q8W
NCT03412747 · Phase 3 · Psoriasis · phase 3
86.1% (n=158) vs 57.9% (n=159) Adalimumab @ 24wk320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
86.5% (n=319) vs 57.9% (n=159) Adalimumab @ 24wk320 mg Q4W + 320 mg Q4W/Q8W
NCT03412747 · Phase 3 · combination · Psoriasis · phase 3
92.6% (n=349) vs 1.2% (n=86) placebo @ 16wk320 mg Q4W
NCT03410992 · Phase 3
85.5% (n=373) vs 78.6% (n=370) Secukinumab @ 16wk320 mg Q4W
NCT03536884 · Phase 3 · registry result, not featured evidence
87.5% (n=32) vs 0% (n=15) placebo @ 16wk320 mg Q4W
NCT05020249 · Phase 3 · registry result, not featured evidence
92% (n=100) vs 3% (n=33) placebo @ 16wkDosage Regimen 1
NCT06011733 · Phase 3 · registry result, not featured evidence
PASI 90 82.6% (n=161) @ 56wk320 mg Q4W/Q8W
responder rate · % of participants
No placebo or comparator arm
NCT03412747 · Phase 3 · Psoriasis · phase 3
show 21 more results
84.8% (n=158) @ 56wk320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
91% (n=100) @ 56wk320 mg Q4W/Q8W
NCT03410992 · Phase 3
86.8% (n=106) @ 56wk320 mg Q4W/Q4W
NCT03410992 · Phase 3
77.6% (n=384) @ 144wk320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
80.2% (n=832) @ 144wk320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
0% (n=70) @ 144wk320mg Q4W
NCT03598790 · Phase 3 · registry result, not featured evidence
95% (n=20) @ 16wk320/160 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
84.4% (n=32) @ 16wk320 mg + PBO
NCT03025542 · Phase 2 · registry result, not featured evidence · combination
70.6% (n=17) @ 16wk320 mg
NCT03025542 · Phase 2 · registry result, not featured evidence
90.5% (n=21) @ 16wk64/32 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
53.5% (n=43) @ 4wk
NCT03230292 · Phase 2 · registry result, not featured evidence
79.1% (n=43) @ 8wk
NCT03230292 · Phase 2 · registry result, not featured evidence
79.1% (n=43) @ 12wk
NCT03230292 · Phase 2 · registry result, not featured evidence
86% (n=43) @ 16wk
NCT03230292 · Phase 2 · registry result, not featured evidence
79.1% (n=43) @ 20wk
NCT03230292 · Phase 2 · registry result, not featured evidence
79.1% (n=43) @ 24wk
NCT03230292 · Phase 2 · registry result, not featured evidence
81.4% (n=43) @ 28wk
NCT03230292 · Phase 2 · registry result, not featured evidence
81.4% (n=43) @ 32wk
NCT03230292 · Phase 2 · registry result, not featured evidence
86% (n=43) @ 36wk
NCT03230292 · Phase 2 · registry result, not featured evidence
76.7% (n=43) @ 40wk
NCT03230292 · Phase 2 · registry result, not featured evidence
86% (n=43) @ 44wk
NCT03230292 · Phase 2 · registry result, not featured evidence
IGA 0/1 83.2% (n=161) @ 56wk320 mg Q4W/Q8W
responder rate · % of participants
No placebo or comparator arm
NCT03412747 · Phase 3 · Psoriasis · phase 3
show 6 more results
82.3% (n=158) @ 56wk320 mg Q4W
NCT03412747 · Phase 3 · Psoriasis · phase 3
76.8% (n=384) @ 144wk320 mg Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
79% (n=832) @ 144wk320 mg Q4W/Q8W
NCT03598790 · Phase 3 · registry result, not featured evidence
0% (n=70) @ 144wk320 mg Q4W
NCT03598790 · Phase 3 · registry result, not featured evidence
95% (n=20) @ 16wk320/160 mg
NCT04718896 · Phase 2 · registry result, not featured evidence
90.5% (n=21) @ 16wk64/32 mg
NCT04718896 · Phase 2 · registry result, not featured evidence

+ 45 further endpoints in the CSV export.

Hidradenitis Suppurativa

Shared mechanism: IL-17A/F · full Hidradenitis Suppurativa pipeline

bimekizumab · Bimzelx

Marketed by UCB

Approved in Hidradenitis Suppurativamonoclonal antibody
Partial signal

NCT04242446 · Phase 3 · completed

This phase 3 trial randomised 505 adults with moderate to severe hidradenitis suppurativa to one of two bimekizumab regimens or placebo, with participants, care providers, investigators and outcome assessors all masked. The primary endpoint was HiSCR50 response at week 16. Regimen 2 exceeded placebo (47.8% vs 28.7%, p=0.006); for regimen 1 (45.3% vs 28.7%, p=0.030) the 97.5% confidence interval for the odds ratio included 1, and the record states that the testing hierarchy failed on this endpoint. The record reports no power calculation or planned enrolment.

Next expected readout: December 2026 · NCT06921850 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results). (met)

Result source: NCT04242498

ORKA-002

Developed by Oruka Therapeutics

Phase 2 in Hidradenitis Suppurativamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2028 · NCT07783542 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Hidradenitis Suppurativa

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

ORKA-002: no structured comparison results are available for Hidradenitis Suppurativa.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

bimekizumab
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 (Week 16): Placebo 28.7 percentage of participants (95% CI 18.1 to 39.3) | BKZ Dosing Regimen 1 45.3 percentage of participants (95% CI 36.8 to 53.8) | BKZ Dosing Regimen 2 47.8 percentage of participants (95% CI 41.8 to 53.7) NCT04242446 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results). NCT04242498 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bimekizumab's landscape · ORKA-002's landscape